Raimundo MD, Arrabal GL, González VK, Álvarez MMC, Aparicio MLR

Language: Spanish
References: 14
Page: 59-66
PDF size: 405.63 Kb.

ABSTRACT

Mycobacterium tuberculosis is responsible for most cases of tuberculosis; the reservoir of infection is the human being with active tuberculosis. It is estimated that tuberculosis affects 1,7 thousand million of individuals worldwide, with eight to 10 million new cases and 1,6 million deaths each year. Certain pathological conditions increase the risk: diabetes mellitus, Hodgkin's lymphoma, chronic lung disease, chronic renal failure, malnutrition, alcoholism and immunosuppression. Infection is the presence of organisms that may or may not cause clinically significant disease. Systemic miliary tuberculosis occurs when the bacteria spread through the systemic arterial system; it is most prominent in the liver, bone marrow, spleen, adrenal, meninges, kidneys, fallopian tubes, ovaries and epididymis, seeded through the blood and it can be the initial manifestation.

REFERENCES

1. Robbins, Kumar V, Abbas A, Fausto N, Aster J. Patología estructural y funcional. 8va ed. España: Elsevier; 2010.

2. Brunham RC. Therapy for acute pelvic inflamatory disease, a critique of recent tratment trial. Am J Obstrt Gynecol. 1984;48:235.

3. Botella Llusiá J. Enfermedad inflamatoria pélvica en las enfermedades de transmisión sexual en la mujer. Barcelona: Salvat; 2015.

4. Velasco-Velázquez MA, Barrera D, González-Arenas A, Rosales C, Agramonte-Hevia J. Macrophage--Mycobacterium tuberculosis interactions: role of complement receptor 3. Microb Pathog [Internet]. 2003 [citado 27 Abr 2016];35(3):125-31. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/12927520

5. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol. 19:93; 2013.

6. Kaufmann Stefan HE. Tuberculosis: Back on the Immunologists' Agenda. Immunity [Internet]. 2006 [citado 22 Abr 2016];24:351-357. Disponible en: http://www.cell.com/immunity/pdf/S1074-7613%2806%2900184-1.pdf

7. Ottenhoff T H, Verreck FA, Hoeve MA, Van de Vosse E. Control of human host immunity to mycobacteria. Tuberculosis (Edinb) [Internet]. 2005 [citado 27 Abr 2016];85(1-2):53-64. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/15687028

8. González-Martín JJ, García-García JM, Anibarro L, Vidal R, Esteban J, Blanquer R, Moreno S, et al. Documento de consenso sobre diagnóstico, tratamiento y prevención de la tuberculosis. Arch Bronconeumol [Internet]. 2010 [citado 27 Abr 2016];46(5):255-64. Disponible en: http://www.archbronconeumol.org/es/documento-consenso-sobre-diagnostico-tratamiento/articulo/S0300289610000785/

9. Schaefer G. Female genital tuberculosis. Clin Obstet Gynecol. 1976;19:223-39.

10. 10.Piura B, Rabinovich A, Leron E, Yanai-Inbar, Mazor M. Peritoneal tuberculosis—an uncommon disease that may deceive the gynecologist. Eur J Obstet Gynecol Reprod Biol [Internet]. 2003 [citado 27 Abr 2016];110(2):230-234. Disponible en: http://www.sciencedirect.com/science/article/pii/S0301211503001015

11. 11.Piura B, Rabinovich A, Leron E, Yaanai-Inbar I, Moshe Mazor M. Peritoneal tuberculosis – an uncommon disease that may deceive the gynaecologist. European J Obstet Gynecol Rep Biol. 2003; 110: 230-4.

12. 12.Raut VS, Mahashur AA, Sheth SS. The Mantoux test in the diagnosis of genital tuberculosis in women. Int J Gynecol Obstet. 2001;72:165-9.

13. 13.Shutherland A. Twenty-five years experience of the drug treatment of tuberculosis of the female genital tract. Br J Obstet Gynecol. 2012;84:881-6.

14. 14.Gómez Vázquez V. Tuberculosis genital. Diagnóstico, tratamiento y secuelas de la enfermedad pélvica inflamatoria [Internet]. Granada: Hospital Universitario Virgen de las Nieves; 2012 Feb 2 [citado 25 Feb 2015]. Disponible en: http://www.hvn.es/servicios_asistenciales/ginecologia_y_obstetricia/ficheros/actividad_docente_e_investigadora/clases_residentes/2012/clase2012_tuberculosis_genital_epi.pdf